LDN for Endometriosis: Pain, Fertility, and Where GLP-1s Fit
Low Dose Naltrexone, commonly called LDN, is increasingly discussed online for endometriosis, pelvic pain, inflammation, fatigue, and fertility. Some posts describe it as though clinical trials have already shown that it reduces endometriosis symptoms or treats the disease.
That conclusion goes beyond the evidence.
One randomized, placebo-controlled endometriosis trial was registered to test 4.5 mg LDN added to norethindrone acetate. It enrolled only nine participants and was terminated after the principal investigator left the institution and funding ended. The trial does not provide the clinical evidence needed to conclude that LDN reduces endometriosis pain, shrinks lesions, prevents recurrence, or improves fertility.
Direct answer: LDN is not an FDA-approved or established treatment for endometriosis. The only registered randomized endometriosis trial enrolled nine participants, ended early, and did not establish efficacy. LDN may still be discussed off label for an individualized symptom goal, but pain support is not the same as controlling lesions or improving fertility. GLP-1 medications may be appropriate for a separate obesity or diabetes indication, not as proven endometriosis treatment.
Explore Patient-Specific Options With Scripx
Interested in a patient-specific LDN prescription? View Scripx Pharmacy's Low Dose Naltrexone product information and ask a licensed prescriber whether an off-label evaluation is appropriate for a defined symptom goal.
Evaluating GLP-1 therapy for a separate metabolic goal? Explore Scripx Pharmacy's medically supervised weight-management services.
Already have a prescription or need help with formulation questions? Contact the Scripx Pharmacy team or learn about Scripx compounding services.
All prescription medications require evaluation by a licensed healthcare provider. LDN use for endometriosis is off label. Compounded medications are not FDA approved. Endometriosis treatment, fertility planning, and metabolic care should be coordinated even when the goals overlap.
Ready to Get Started?
Explore available treatment options and complete a secure health questionnaire for provider review.
View Products & Start Your Order →Prescription medications require an individual medical evaluation and, when appropriate, a prescription from a licensed healthcare provider. Completing a questionnaire does not guarantee treatment or a prescription.
Endometriosis Is More Than One Kind of Pain
Endometriosis is a chronic condition in which tissue resembling the lining of the uterus is found outside the uterus. It can be associated with painful periods, persistent pelvic pain, pain during or after sex, painful bowel movements or urination, fatigue, and difficulty becoming pregnant.
Symptoms and disease burden do not always move together. Some people have extensive disease with limited pain, while others have severe pain with less visible disease. Pain may also continue after lesions have been treated because inflammation, pelvic-floor dysfunction, nerve sensitization, scar tissue, bowel or bladder disorders, migraine, sleep disruption, or another pain condition may contribute.
That complexity creates several separate treatment questions:
Does a treatment reduce pain or improve daily function?
Does it suppress or remove endometriosis lesions?
Does it prevent recurrence or reduce the need for surgery?
Does it improve spontaneous pregnancy, assisted-reproduction outcomes, or live birth?
Does it address a separate metabolic condition without complicating endometriosis care?
The European Society of Human Reproduction and Embryology, or ESHRE, separates endometriosis care into pain management and infertility management because the goals, evidence, and treatment choices differ. Review the ESHRE endometriosis guideline.
What Is Low Dose Naltrexone?
Naltrexone is an opioid receptor antagonist. FDA-approved oral naltrexone is used for specific alcohol- and opioid-related indications, commonly as a 50 mg tablet. Low Dose Naltrexone describes clinician-directed use at substantially lower doses for purposes outside the approved labeling.
There is no FDA-defined LDN product and no FDA-approved naltrexone indication for endometriosis, pelvic pain, inflammation, infertility, or weight loss. A patient-specific compounded low-dose formulation is also not FDA approved.
LDN is discussed in chronic-pain research because investigators have proposed effects involving opioid signaling, microglial activity, pain processing, and selected inflammatory pathways. These hypotheses make further study reasonable. They do not prove an effect on endometriosis lesions, estrogen-driven disease activity, adhesions, ovarian reserve, implantation, or live birth.
For a broader foundation, read what Low Dose Naltrexone is, including its uses, evidence, safety, and compounding.
What Did the Registered LDN Endometriosis Trial Study?
The most important direct evidence source is ClinicalTrials.gov record NCT03970330. The randomized, quadruple-masked trial planned to compare:
4.5 mg naltrexone daily plus standard treatment with norethindrone acetate
Placebo plus the same standard hormonal treatment
The proposed 12-week study was designed to assess patient-reported endometriosis pain and quality of life. It was not designed to establish that LDN alone treats endometriosis, because both groups received norethindrone acetate.
The trial enrolled nine participants. Its registry status is terminated, with the reason recorded as the original principal investigator leaving the institution and a lack of funding to continue. Review the trial record.
This distinction is crucial: registration shows that researchers intended to test a question. It does not show that the treatment worked.
Because the study ended after only nine participants, it cannot establish:
Reliable pain reduction
Improved quality of life
Reduced lesion burden
Less recurrence
Avoidance of surgery
Improved fertility or pregnancy outcomes
Superiority to hormonal treatment alone
Which patients are most likely to respond
The trial's termination was operational, not proof that LDN failed or caused harm. It is equally important not to interpret the absence of a result as evidence that LDN works. The scientifically accurate conclusion is that the endometriosis-specific efficacy question remains unanswered.
LDN for Endometriosis: Evidence at a Glance
Why Chronic-Pain Evidence Cannot Be Relabeled as Endometriosis Evidence
LDN has been evaluated in fibromyalgia and other chronic-pain settings. Some small studies have reported symptom signals, while other controlled trials have not found a meaningful advantage over placebo. Even a positive result in another pain condition would not establish efficacy for endometriosis.
The sources of pain differ. Endometriosis-associated pain may involve lesions, cyclical inflammation, deep infiltrating disease, adhesions, nerve involvement, pelvic-floor dysfunction, bowel or bladder symptoms, and central sensitization. An intervention that changes pain processing might help a symptom without changing the underlying lesions.
That possibility is not meaningless. Improving pain, sleep, fatigue, or function can matter greatly. It simply must be measured and described honestly.
If an off-label LDN trial is considered, a useful plan should define:
The exact symptom being targeted
A baseline score for pain interference or function
Menstrual timing and symptom pattern
Current hormonal and nonhormonal treatments
A reassessment date
The minimum change that would justify continuing
A stop plan if benefit is absent or adverse effects occur
Continued gynecologic follow-up for disease-directed care
Does LDN Treat Endometriosis Lesions?
That has not been established.
Online explanations often move from “endometriosis involves inflammation” to “LDN may affect inflammation” and then to “LDN treats endometriosis.” The final step is unsupported. A plausible biological pathway is a reason to conduct a trial, not proof of lesion regression or disease modification.
To establish lesion control, research would need appropriate endometriosis-specific outcomes, such as validated imaging where applicable, surgical findings, recurrence, repeat procedures, or other accepted disease measures. The terminated nine-person trial did not answer those questions.
LDN should not be presented as a replacement for hormonal suppression, surgery, pelvic-floor therapy, fertility care, or another evidence-based strategy selected by the treating clinician.
Does LDN Improve Fertility in Endometriosis?
There is no adequate evidence that LDN improves fertility outcomes in people with endometriosis.
Pain improvement is not a fertility endpoint. A change in inflammation theory is not proof of implantation. A pregnancy anecdote cannot establish causation because fertility outcomes are affected by age, ovarian reserve, tubal anatomy, sperm factors, disease location, previous surgery, concurrent treatment, and chance.
Meaningful fertility research should assess outcomes such as:
Ovulation when relevant
Time to pregnancy
Clinical pregnancy
Miscarriage
Assisted-reproduction outcomes
Live birth
The registered LDN trial excluded people who were pregnant, breastfeeding, or trying to conceive. It therefore was not designed to establish LDN as a fertility treatment.
Someone who is trying to conceive or planning fertility treatment should review every prescription, compounded medication, supplement, and weight-management drug with the reproductive specialist and pharmacist. Treatment decisions may change as the goal shifts from pain suppression to conception.
Where Do GLP-1 Medications Fit?
Semaglutide and tirzepatide are not established treatments for endometriosis. Current endometriosis guidelines do not recommend GLP-1 therapy to reduce lesions, relieve endometriosis pain, or improve fertility.
The responsible crossover is through a separate approved metabolic indication. A person with endometriosis may also have obesity, type 2 diabetes, cardiovascular risk, obstructive sleep apnea, or another condition for which a specific GLP-1 or GIP/GLP-1 product may be appropriate.
Researchers are studying how GLP-1 signaling may affect reproductive tissues, inflammation, fibrosis, and endometrial function. Much of that discussion is mechanistic, indirect, preclinical, or focused on obesity, diabetes, PCOS, endometrial hyperplasia, and endometrial cancer rather than endometriosis treatment. A 2025 review described potential effects on endometrial and peritoneal environments but emphasized the need for dedicated reproductive-health research. Review the peer-reviewed article.
The correct interpretation is:
GLP-1 research creates hypotheses relevant to reproductive health.
Approved GLP-1 therapies can have established metabolic uses.
Neither point proves that a GLP-1 medication treats endometriosis.
Gastrointestinal Symptoms Can Overlap
Endometriosis may cause abdominal pain, bloating, constipation, diarrhea, painful bowel movements, nausea, or symptoms that vary with the menstrual cycle. GLP-1 medications commonly cause gastrointestinal effects, including nausea, vomiting, diarrhea, constipation, abdominal discomfort, and delayed stomach emptying.
When symptoms overlap, it can be difficult to determine whether a change reflects:
Endometriosis activity
A medication effect
Reduced food or fluid intake
Constipation or another gastrointestinal condition
A new problem requiring evaluation
Starting multiple therapies at the same time makes this harder. A coordinated plan should document baseline symptoms, hydration, nutrition, bowel patterns, and the timing of medication changes.
Persistent or severe abdominal pain should not automatically be attributed to endometriosis or dismissed as an expected GLP-1 effect. It requires appropriate clinical assessment.
Contraception and Pregnancy Planning Matter
Hormonal therapy is commonly used to manage endometriosis-related pain. GLP-1 treatment introduces additional reproductive planning considerations.
Current Wegovy labeling says the medication may harm an unborn baby and should be stopped two months before a planned pregnancy. Review the current Wegovy prescribing information.
Current Zepbound labeling says pregnancy may involve fetal harm and warns that oral birth-control pills may not work as well for four weeks after starting tirzepatide and for four weeks after each dose increase. It advises discussing another contraceptive method during those periods. Review the current Zepbound prescribing information.
The exact plan depends on the medication, indication, contraception method, pregnancy goals, and treating clinicians. Patients should not stop hormonal endometriosis therapy, LDN, a GLP-1 medication, or contraception without individualized guidance.
Before treatment, discuss:
Whether pregnancy is possible or desired
The current endometriosis treatment plan
Whether oral contraception is being used for pregnancy prevention, symptom suppression, or both
Whether the exact GLP-1 product affects contraception planning
When a medication should be stopped before trying to conceive
Upcoming fertility evaluation or assisted reproduction
Nutrition and prenatal planning
What to do if pregnancy occurs unexpectedly
Procedures, Anesthesia, and Opioid Pain Treatment
Medication coordination is especially important when endometriosis care may involve laparoscopy, egg retrieval, another fertility procedure, emergency treatment, or surgery.
Naltrexone blocks opioid receptors. It can interfere with opioid pain relief and may precipitate withdrawal in a person who is physiologically dependent on an opioid. Patients should ensure that the gynecologist, fertility specialist, surgeon, anesthesiologist, dentist, emergency clinician, prescriber, and pharmacist know about LDN use.
GLP-1 medications can delay stomach emptying. Current Wegovy and Zepbound labeling instructs patients to tell clinicians before procedures involving anesthesia or deep sedation because retained stomach contents can increase aspiration risk.
These issues require a clinician-directed plan. Patients should not create their own opioid-free interval, stop LDN or a GLP-1 before a procedure, or attempt to overcome opioid blockade without direct guidance.
Read LDN side effects and opioid safety and the broader guide to LDN interactions involving opioids, GLP-1s, and other medications.
Can LDN and a GLP-1 Be Used Together?
There is no universal rule that automatically prevents every patient from being prescribed LDN with semaglutide or tirzepatide. Direct studies of an LDN-plus-GLP-1 combination in endometriosis are lacking.
If both are considered, each medication should have a separate purpose, evidence discussion, and monitoring plan. The care team should review:
All prescriptions, over-the-counter products, and supplements
Opioid exposure and upcoming procedures
Endometriosis treatment and symptom pattern
Baseline nausea, constipation, diarrhea, bloating, and abdominal pain
Hydration, nutrition, protein intake, and weight trajectory
Diabetes medications and glucose status
Contraception and pregnancy plans
Fertility-treatment timing
Whether one medication should be started before the other so response is interpretable
There is no established evidence that LDN enhances GLP-1 weight loss, prevents GLP-1 adverse effects, improves fertility, or turns GLP-1 therapy into an endometriosis treatment.
LDN is also not the same as Contrave, an FDA-approved extended-release product containing naltrexone and bupropion. Evidence for that combination cannot be transferred to compounded LDN.
Where Does Retatrutide Fit?
Retatrutide is an investigational agonist of the GIP, GLP-1, and glucagon receptors. It is not FDA approved and is not available for routine prescribing.
There is no established evidence that retatrutide treats endometriosis, pelvic pain, lesions, or infertility. It should not be presented as part of an LDN combination protocol.
FDA states that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. Review FDA's current statement.
Questions to Ask the Gynecologist, Prescriber, and Pharmacist
What is the exact goal: pain, function, lesion control, fertility, or metabolic health?
Which endometriosis treatments should continue?
What direct evidence supports LDN for this goal?
How will symptom response be measured?
When will the treatment be reassessed or stopped?
Is an opioid being used now or likely to be needed for a procedure?
Could gastrointestinal effects obscure an endometriosis symptom?
Is pregnancy possible, desired, or being actively pursued?
Does the current contraception plan need review before tirzepatide?
When should the exact GLP-1 medication be stopped before pregnancy or a procedure?
The Bottom Line
Interest in LDN for endometriosis is ahead of the clinical evidence. One randomized trial was designed to test 4.5 mg LDN as an add-on to norethindrone acetate, but it enrolled only nine participants and terminated when the investigator left and funding ended. It did not establish that LDN reduces endometriosis pain, treats lesions, prevents recurrence, avoids surgery, or improves fertility.
An individualized, clinician-supervised LDN discussion may still focus on a defined symptom goal. That is different from presenting LDN as disease-modifying endometriosis treatment or a fertility therapy.
GLP-1 medications add a relevant but separate care pathway. Semaglutide or tirzepatide may be appropriate for an approved metabolic indication in a person who also has endometriosis. They are not proven endometriosis treatments. Gastrointestinal symptoms, oral contraception, pregnancy plans, fertility procedures, anesthesia, nutrition, and medication timing all make coordination essential.
The clearest framework is simple: pain support, endometriosis control, fertility care, and metabolic treatment may intersect, but they are not interchangeable.
Talk With Scripx Pharmacy About a Patient-Specific Prescription
If a licensed prescriber believes LDN may be appropriate for an individualized symptom goal, review Scripx Pharmacy's LDN information and contact a Scripx compounding pharmacist to discuss the prescription, formulation, inactive ingredients, opioid safety, and procedure coordination.
If semaglutide, tirzepatide, or another therapy is being evaluated for a separate metabolic indication, explore Scripx Pharmacy's medically supervised weight-management services and include the gynecology or fertility team in the plan.
Do not stop hormonal therapy, fertility treatment, LDN, an opioid, contraception, or a GLP-1 medication without guidance from the clinician managing that part of care. LDN use for endometriosis is off label. Compounded medications are not FDA approved. Retatrutide remains investigational and cannot legally be compounded.
This article is provided for general education and does not replace individualized medical advice. Publication should include the name and credentials of the clinical reviewer and the date reviewed.
FAQ Package
Is LDN FDA approved for endometriosis?
No. Naltrexone is FDA approved for specific alcohol- and opioid-related indications. Low-dose use for endometriosis or chronic pelvic pain is off label, and a patient-specific compounded LDN preparation is not FDA approved.
Has LDN been studied for endometriosis?
One randomized trial was registered to study 4.5 mg LDN added to norethindrone acetate. It enrolled nine participants and was terminated after the principal investigator left and funding ended. It did not establish efficacy.
Does LDN reduce endometriosis pain?
That remains unproven. LDN has mixed evidence in other chronic-pain conditions, but evidence from another diagnosis cannot establish endometriosis-specific pain relief.
Can LDN shrink endometriosis lesions?
No adequate clinical evidence shows that LDN shrinks lesions, suppresses endometriosis, or prevents recurrence.
Does LDN improve fertility with endometriosis?
There is no adequate evidence that LDN improves implantation, pregnancy, or live-birth outcomes in endometriosis. The registered trial excluded people who were trying to conceive.
Can LDN replace hormonal therapy or surgery?
No comparative evidence supports replacing established endometriosis treatment with LDN. Any add-on symptom strategy should preserve appropriate gynecologic monitoring and disease-directed care.
Do GLP-1 medications treat endometriosis?
Semaglutide and tirzepatide are not established endometriosis treatments. A specific product may be appropriate for a separate FDA-approved metabolic indication after individualized evaluation.
Can LDN and a GLP-1 be taken together?
There is no universal prohibition, but direct endometriosis studies of the combination are lacking. Each medication should have a separate goal, and the prescriber and pharmacist should review gastrointestinal symptoms, nutrition, pregnancy plans, procedures, and opioid exposure.
What should someone planning pregnancy know about GLP-1 therapy?
The plan depends on the exact product. Current Wegovy labeling advises stopping two months before planned pregnancy. Current Zepbound labeling warns of fetal harm and says oral birth-control pills may be less effective for four weeks after starting and after each dose increase. Coordinate with the prescribing and fertility teams.
Can retatrutide be used or compounded for endometriosis?
No. Retatrutide is investigational and not FDA approved. FDA states that it cannot be used in compounding under federal law. There is no established evidence that it treats endometriosis.